AI Article Synopsis
- A 73-year-old patient with Parkinsonian-type multiple system atrophy (MSA-P) experienced motor symptoms, including gait disturbances and swallowing difficulties, prompting medical evaluation.
- Brain imaging and diagnostic tests confirmed MSA-P, but traditional Parkinson’s treatments showed minimal effectiveness as the patient's condition worsened.
- After undergoing Lee Silverman Voice Treatment (LSVT-LOUD) at age 75, the patient showed significant improvements in speech volume, swallowing abilities, and cognitive function, indicating potential benefits of LSVT-LOUD for patients with MSA-P.
Article Abstract
We describe a case of Parkinsonian-type multiple system atrophy (MSA-P) treated with Lee Silverman Voice Treatment (LSVT-LOUD; LSVT Global, Inc., Phoenix, AZ, USA). At age 73, the patient developed motor symptoms, including gait disturbances with a tendency to fall, as well as swallowing difficulties and impaired dexterity in his right hand, prompting a visit to our hospital. Brain magnetic resonance imaging (MRI) revealed atrophy in the cerebellum and brainstem, particularly in the pons, along with enlargement of the fourth ventricle; however, the "cross sign" on the pons was not clearly visible. Dopamine transporter single-photon emission computed tomography (DAT-SPECT) showed decreased nuclide accumulation in the striatum. Additionally, I-MIBG cardiac scintigraphy demonstrated preserved nuclide accumulation in the heart. L-dopa challenge tests were conducted, but no significant improvement in motor symptoms was observed. Based on these findings, he was diagnosed with MSA-P. Over the following years, his condition progressively worsened, with increasing orthostatic hypotension, dysphagia, and falls. Various treatments, including anti-Parkinson's medications and vasopressors, provided little relief. At age 75, due to severe dysphagia and hoarseness, he was admitted for LSVT-LOUD therapy. After LSVT-LOUD treatment, the patient improved voice volume, tongue pressures, alternating motion rates of "pa," "ta," and "ka," and the Frontal Assessment Battery (FAB) score. These results suggest that LSVT-LOUD may positively impact both speech and swallowing functions, as well as frontal lobe function. Larger studies are needed to validate these results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624014 | PMC |
| http://dx.doi.org/10.7759/cureus.73106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical toxicology profile of squalene epoxidase inhibitors.
Toxicol Appl Pharmacol
August 2020
Agios Pharmaceuticals, Inc., 88 Sidney St, Cambridge, MA 02139, USA. Electronic address:
Small cell lung cancer (SCLC) is a particularly aggressive subset of lung cancer, and identification of new therapeutic options is of significant interest. We recently reported that SCLC cell lines display a specific vulnerability to inhibition of squalene epoxidase (SQLE), an enzyme in the cholesterol biosynthetic pathway that catalyzes the conversion of squalene to 2,3-oxidosqualene. Since it has been reported that SQLE inhibition can result in dermatitis in dogs, we conducted a series of experiments to determine if SQLE inhibitors would be tolerated at exposures predicted to drive maximal efficacy in SCLC tumors.
View Article and Find Full Text PDFPhase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Clin Pharmacol Drug Dev
February 2019
Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Pyruvate kinase deficiency is a chronic hemolytic anemia caused by mutations in PK-R, a key glycolytic enzyme in erythrocytes. These 2 phase 1 randomized, placebo-controlled, double-blind healthy-volunteer studies assessed the safety, tolerability, and pharmacokinetics/pharmacodynamics of AG-348, a first-in-class allosteric PK-R activator. Twelve sequential cohorts were randomized 2:6 to receive oral placebo or AG-348, respectively, as a single dose (30-2500 mg) in the single-ascending-dose (SAD) study (ClinicalTrials.
View Article and Find Full Text PDFDiscovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
ACS Med Chem Lett
April 2018
Agios Pharmaceuticals Inc., Cambridge, Massachusetts 02139, United States.
Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation. IDH1 mutations have been described in an array of hematologic malignancies and solid tumors.
View Article and Find Full Text PDFAG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.
Blood
September 2017
Agios Pharmaceuticals, Inc., Cambridge, MA; and.
Pyruvate kinase (PK) deficiency is a rare genetic disease that causes chronic hemolytic anemia. There are currently no targeted therapies for PK deficiency. Here, we describe the identification and characterization of AG-348, an allosteric activator of PK that is currently in clinical trials for the treatment of PK deficiency.
View Article and Find Full Text PDFAG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Mutations.
Cancer Discov
May 2017
Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
Somatic gain-of-function mutations in isocitrate dehydrogenases () 1 and 2 are found in multiple hematologic and solid tumors, leading to accumulation of the oncometabolite ()-2-hydroxyglutarate (2HG). 2HG competitively inhibits α-ketoglutarate-dependent dioxygenases, including histone demethylases and methylcytosine dioxygenases of the TET family, causing epigenetic dysregulation and a block in cellular differentiation. studies have provided proof of concept for mutant IDH inhibition as a therapeutic approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!